Improving colorectal cancer screening programs

Area of Science:

• Gastroenterology and Oncology
• Biomarker Discovery
• Public Health Policy

Background:

• Colorectal cancer screening is crucial for reducing mortality, with colonoscopy as the gold standard but facing low adherence.
• Current fecal tests improve accessibility but also suffer from low participation rates.
• Emerging screening methods aim to increase adherence by offering diverse, convenient options.

Discussion:

• New blood tests detecting circulating tumor DNA (ctDNA) show accuracy for cancer but are less sensitive for precancerous lesions compared to stool tests.
• Immune system-related biomarkers, such as sCD26, are being explored for early colorectal cancer detection, potentially identifying disease before fecal blood is present.
• The development of tests based on blood, urine, or saliva could facilitate earlier screening through routine primary care visits.

Key Insights:

• Novel screening strategies are essential to overcome low participation rates in current colorectal cancer screening programs.
• Blood-based biomarkers, including immune markers and ctDNA, offer potential for earlier and more accessible colorectal cancer detection.
• Integrating new screening tests into primary healthcare could significantly broaden population reach and improve adherence.

Outlook:

• Future colorectal cancer screening may involve a multi-test approach, leveraging the strengths of various biomarkers and sample types.
• Expanding screening eligibility to younger age groups through accessible primary care tests is a key future direction.
• Continued research into immune system interactions with cancer holds promise for developing highly sensitive and specific early detection biomarkers.